Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)
Evidence-based recommendations on acalabrutinib (Calquence) for treating chronic lymphocytic leukaemia in adults
Search results
27 results
-
-
Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)
NICE is unable to make a recommendation on teduglutide (Revestive) for short bowel syndrome in people 1 year and over because Takeda withdrew its evidence
-
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults
-
Avelumab for treating metastatic Merkel cell carcinoma (TA517)
Evidence-based recommendations on avelumab (Bavencio) for metastatic Merkel cell carcinoma in adults
-
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal) (TA686)
NICE is unable to make a recommendation on blinatumomab (Blincyto) for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia in
-
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA687)
Evidence-based recommendations on ribociclib (Kisqali) for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally
-
Anakinra for treating Still's disease (TA685)
Evidence-based recommendations on anakinra (Kineret) for treating adult-onset Still’s disease and systemic juvenile idiopathic arthritis in people 8 months and
-
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)
Evidence-based recommendations on selective internal radiation therapies SIR-Spheres (Sirtex), TheraSphere (BTG) and QuiremSphere (Quirem Medical) for treating
-
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in
-
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (TA683)
Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung
-
Erenumab for preventing migraine (TA682)
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults
-
Baricitinib for treating moderate to severe atopic dermatitis (TA681)
Evidence-based recommendations on baricitinib for treating moderate to severe atopic dermatitis in adults
-
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple
-
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
-
Safeguarding adults in care homes (NG189)
This guideline covers keeping adults in care homes safe from abuse and neglect. It includes potential indicators of abuse and neglect by individuals or organisations, and covers the safeguarding process from when a concern is first identified through to section 42 safeguarding enquiries. There are recommendations on policy, training, and care home culture, to improve care home staff awareness of safeguarding and ensure people can report concerns when needed.
-
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults
-
Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma in adults who have
-
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)
Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults
-
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA678)
NICE is unable to make a recommendation on omalizumab (Xolair) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals
-
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (TA673)
Evidence-based recommendations on niraparib for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary
-
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
NICE is unable to make a recommendation on pembrolizumab (Keytruda) for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when
-
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal) (TA675)
NICE is unable to make a recommendation on vernakalant (Brinavess) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. This
-
Trabectedin for the treatment of advanced soft tissue sarcoma (TA185)
Evidence-based recommendations on trabectedin (Yondelis) for treating advanced soft tissue sarcoma (tumours/cancer)
-
Mepolizumab for treating severe eosinophilic asthma (TA671)
Evidence-based recommendations on mepolizumab (Nucala) for treating severe eosinophilic asthma in adults
-
Brolucizumab for treating wet age-related macular degeneration (TA672)
Evidence-based recommendations on brolucizumab (Beovu) for treating wet age-related macular degeneration in adults
-
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma in adult
-
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor (TA670)
Evidence-based recommendations on brigatinib (Alunbrig) for anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer that has not been